Boosted
cytidine analogue
reverse transcriptase inhibitor antiretroviral compound is a new therapeutic
anti HIV option, in combination with another
drug such as a NRTI or a
protease inhibitor. It's heightened and sustained antiretroviral
potency is due to the increased
intracellular level of 3TC triphosphate, the active form of 3TC. This effect is obtained by combining 3TC, in usual doses, with a
reduced dose of ddC, in the same
pharmaceutical formulation. The product could be administered twice or even once daily, which is convenient, and does not increase the
pill burden for the patient. The reduced ddC dosage prevents the occurrence of ddC related side effects. Other
cytidine derivatives (racemic or negative enantiomers) could have the same effects as ddC and could probably be combined with 3TC, and have the same effect. On the other hand,
low dose ddC may also increase the
intracellular levels of other
cytidine derivatives as it does for 3TC. Boosted cytidine analogue
reverse transcriptase inhibitor antiretroviral compound could also be formulated in combination with another
drug such as another NRTI (e.g.
abacavir) or any
protease inhibitor in the same
capsule or tablet. This approach offers a dual anti-HIV therapy that is as efficacious as the routine triple therapy. In this way the HIV treatment cost could be significantly reduced which is imperative for resource-poor settings. This new formulation is convenient and well tolerated with no additional
toxicity than that of the combining
drug (NRTI or
protease inhibitor) and 3TC. Moreover, this will enable a larger number of patients to benefit from the already known 3TC effects. It will also increase the 3TC effects in those organs or HIV sanctuaries with usually reduced 3TC concentrations or activity. It could be indicated in both the initial as well as in salvage HIV therapy. It could also be used for therapy optimization or simplification. Moreover, in combination with another NRTI such as
abacavir, or even alone, it could be beneficial for reducing the HIV harm in resource-poor settings.